Article 141(1) opinions on any scientific matter: veterinary medicines

This page lists the opinions drawn up by the Committee for Veterinary Medicinal Products (CVMP) under Article 141(1)(c), (e) and (i) of the Veterinary Medicinal Product Regulation on any scientific matter related to medicines for use in animals.

The Committee must draw up an opinion on any scientific matter at the request of the Executive Director of the European Medicines Agency or of the European Commission under Article 141(1)(c). It may also draw up an opinion following a request from a Member State under Article 141(1)(e).

In line with Article 141(1)(i), the Committee may also provide scientific advice on the use of antimicrobials and antiparasitics in animals to minimise the development of antimicrobial resistance in the European Union.

Where the scientific issue concerns both human and veterinary medicines, the Committee may adopt a common opinion with the Committee for Medicinal Products for Human Use (CHMP).

Since January 2022, requests previously falling under Article 30(3) of Regulation (EC) No 726/2004 fall under Article 141(1)(c) and Article 141(1)(e) of Regulation (EU) No 2019/6.

For more information:

• Referral procedures: veterinary medicines
• Veterinary Medicinal Products Regulation

Advice on use of antimicrobials and antiparasitics

Select the expandable panel below to access all pages related to Article 141(1)(i) procedures.

See pages

Find below the links to the pages related to Article 141(1)(i) procedures, including all relevant documents:

• Quarter-based selective dry cow therapy - referral
• Veterinary medicinal products containing amoxicillin - referral

Opinions requested by the Executive Director of EMA or of the EC

There are currently no procedures started under Article 141(1)(e).

Opinion requested by a Member State

There are currently no procedures started under Article 141(1)(c).

Opinions under Article 30(3) of Regulation (EC) No 726/2004

Select the expandable panels below to find a list of the pages related to procedures under Article 30(3) of Regulation (EC) No 726/2004.

Since January 2022, these types of opinions fall under Articles 141(1)(c) and 141(1)(e) of Regulation (EU) 2019/6.

Dapsone as an impurity in veterinary medicinal products containing sulphamethoxazole or other sulphonamides

Opinion of the CVMP pursuant to Article 30(3) of Regulation (EC) No 726/2004 of the European Parliament and of the Council on dapsone as an impurity in veterinary medicinal products containing sulphamethoxazole or other ...

Reference Number: EMA/CVMP/392253/2012

CVMP assessment report under Article 30(3) of Regulation (EC) No 726/2004 for dapsone as an impurity in veterinary medicinal products containing sulphamethoxazole or other sulphonamides

Adopted Reference Number: EMA/CVMP/392271/2012

Histamine residues in veterinary medicinal products containing gentamicin for parental administration to horses

CVMP assessment report regarding the request for an opinion under Article 30(3) of Regulation (EC) No. 726/2004

Reference Number: EMA/CVMP/766265/2018

Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004

Reference Number: EMA/CVMP/727329/2018

Potential risk for the consumer resulting from the use of lidocaine in food producing species

CVMP assessment report regarding the request for an opinion under Article-30(3) of Regulation (EC) No 726/2004 in relation to the potential risk for the consumer resulting from the use of lidocaine in food producing spec...

Adopted Reference Number: EMA/CVMP/118717/2015

Opinion of the Committee for Medicinal Products for Veterinary Use regarding a request pursuant to Article-30(3) of Regulation (EC) No 726/2004 in relation to the potential risk for the consumer resulting from the use of...

Reference Number: EMA/CVMP/124059/2015

Request for an opinion regarding a request pursuant to Article-30(3) of Regulation (EC) No 726/2004 in relation to the potential risk for the consumer resulting from the use of lidocaine in food producing species

Retrovirus RD114 in live attenuated vaccines for use in animals

Public statement on the evaluation of the compliance of marketing authorisation holders with CVMP Risk Management Strategy with respect to potential presence of RD114 in feline and canine vaccines

Reference Number: EMA/CVMP/814776/2018

CVMP Risk Management Strategy - Managing the risk of the potential presence of replication competent endogenous retrovirus RD114 in starting materials and final products of feline and canine vaccines

Reference Number: EMA/CVMP/IWP/592652/2014

Opinion of the CVMP pursuant to Article 30(3) of Regulation (EC) No 716/2004 of the European Parliament and of the Council on retrovirus RD114 in live attenuated vaccines for use in animals

Reference Number: EMA/CVMP/433418/2010

CVMP assessment report: feline endogenous retrovirus RD114 in some live attenuated vaccines commercially available in the EU for use in animals

Reference Number: EMA/CVMP/300321/2010

Risk for the consumer resulting from the use of diethanolamine as an excipient in veterinary medicinal products for food-producing species

CVMP assessment report regarding the request for an opinion under Article 30(3) of Regulation (EC) No. 726/2004 in relation to the potential risk for the consumer resulting from the use of diethanolamine as an excipient ...

Adopted Reference Number: EMA/CVMP/468348/2018

Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004 on the potential risk for the consumer resulting from the use of diethanolamine as an excipient ...

Reference Number: EMA/CVMP/473059/2018

Public consultation concerning a request for CVMP opinion under Article 30(3) of Regulation (EC) No 726/2004 on the risk for the consumer resulting from the use of diethanolamine as an excipient in veterinary medicinal p...

Draft: consultation closed Consultation dates: 16/03/2018 to 14/05/2018 Reference Number: EMA/CVMP/157690/2018 Summary:

The European Medicines Agency is seeking stakeholder input on any information or data that may help its Committee for Medicinal Products for Veterinary Use (CVMP) to reach an opinion on consumer risk from using diethanolamine as an excipient in veterinary medicines for food-producing animals.

Risks to vultures and other necrophagous bird populations in the Union in connection with the use of veterinary medicinal products containing the substance diclofenac

CVMP assessment report under Article 30(3) of Regulation (EC) No 726/2004 on the risk to vultures and other necrophagous bird populations in the European Union in connection with the use of veterinary medicinal products ...

Adopted Reference Number: EMA/CVMP/721170/2014

Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004 - On the risk to vultures and other necrophagous bird populations in the European Union in conne...

Reference Number: EMA/CVMP/761582/2014

Overview of comments received on public consultation regarding the request to the European Medicines Agency from the European Commission for a scientific opinion regarding the risks to vultures and other necrophagous bir...

Reference Number: EMA/715812/2014

Consultation procedure - Public consultation regarding the request to the European Medicines Agency from the European Commission for a scientific opinion regarding the risks to vultures and other necrophagous bird popula...

Draft: consultation closed Consultation dates: 12/09/2014 to 10/10/2014 Reference Number: EMA/545597/2014 Summary:

The European Medicines Agency would like to consult stakeholders on the questions posed to the

Agency in the request for a scientific opinion regarding the risks to vultures and other necrophagous

bird populations in the Union in connection with the use of veterinary medicinal products containing the

substance diclofenac.

Request for an opinion regarding the risks to vultures and other necrophagous bird populations in the Union in connection with the use of veterinary medicinal products containing the substance diclofenac

Template for comments - Public consultation regarding the request to the European Medicines Agency from the European Commission for a scientific opinion regarding the risks to vultures and other necrophagous bird populat...

Page update history

An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.

The tracking of updates begins in March 2026.

See update history

12 March 2026

New 'Scientific advice on the use of antimicrobials and antiparasitics' section added to link pages related to Article 141(1)(i) procedures. 

Documents related to Article 30(3) of Regulation (EC) No 726/2004 procedures moved to a new section.